Homepage
Author:
AB Science
Posted Date:
April 27, 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
AB Science
April 27, 2026
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
AB Science
April 20, 2026
AB Science provides an update on its clinical development program.
AB Science
April 16, 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
AB Science
February 24, 2026
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
AB Science
February 9, 2026
AB Science reçoit un avis d’autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant
AB Science
January 29, 2026
AB Science obtient un brevet japonais pour l’utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu’en 2041
AB Science
January 27, 2026
